Summary:
A randomized, double-blind, placebo-controlled, parallel
group study to evaluate the efficacy and safety of CNP520
in participants at risk for the onset of clinical symptoms of
Alzheimer’s Disease (AD)
Qualified Participants Must:
• Male or female, age 60 to 75 years
•
Willing to have a study partner throughout the study
Qualified Participants May Receive:
Compensation for time and travel